RUNX1-RUNX1T1 (AML1-ETO) t(8;21) Quantitative Test – UAE Molecular MRD Monitoring

Executive Summary & Core Metrics

●Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189 & ISO 9001:2015 Accredited Processing, in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of ICT in Health Fields.
●Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AM – 11 PM) for peripheral blood; bone marrow collection requires hospital visit.
●Clinical Guidance: Complimentary Telephonic Post-Test Clinical Guidance by DHA-licensed professionals.
●Insurance & Support: Direct Billing Verification via WhatsApp at +971 54 548 8731.

Test Overview & Methodology

The RUNX1-RUNX1T1 (AML1-ETO) t(8;21) Quantitative test precisely measures residual leukemic cells harboring the t(8;21) chromosomal translocation using Real-Time Quantitative PCR (qPCR). This assay is the gold standard for monitoring minimal residual disease (MRD) in adult and pediatric Acute Myeloid Leukemia (AML), enabling treatment stratification and early relapse detection.

Feature	Our Test (qPCR)	Closest Alternative (FISH/Karyotyping)
Precision	Quantitative MRD to 10⁻⁵ sensitivity	Qualitative detection, low sensitivity (10⁻²)
Methodology	Real-Time qPCR (LC-MS/MS calibrated)	Fluorescence in Situ Hybridization (FISH)
Turnaround Time	3–4 days	5–10 days

Physician Insight & Safety Protocols

“As a specialist in diagnostic radiology, I understand the critical role molecular monitoring plays in oncology. This quantitative PCR test offers a highly sensitive window into your molecular response, but it must always be interpreted alongside your full clinical picture and never in isolation.” — Mr. Prabhakar Reddy Kalathoor, DHA Registration ID: 61713011.

Medication Advisory

Do not discontinue prescribed chemotherapy, targeted therapy, or supportive medications without consulting your treating oncologist. Any change in management must be based on comprehensive disease evaluation.

Exclusion Criteria & Emergency Red Flags

Test may be deferred or results interpreted with caution if:

Active systemic infection or recent blood transfusion (within 2 weeks).
Pregnancy – MRD monitoring schedule may be adjusted; always inform your hematologist.
Inadequate specimen (clotted, hemolyzed) or improper cold-chain transport.

Seek immediate medical attention (Emergency Room) if you experience:

Fever >38.3°C, uncontrolled bleeding, or new neurological symptoms.
Rapid rise in RUNX1-RUNX1T1 transcript levels reported by your oncologist.

Patient FAQ & Clinical Guidance

1. What does the RUNX1-RUNX1T1 quantitative test measure?

A: It measures the number of leukemia-specific RUNX1-RUNX1T1 fusion gene copies in your blood or bone marrow, reflecting residual disease. This molecular monitoring test is essential after initial AML treatment to detect early relapse, assess remission depth, and guide consolidation therapy decisions.

2. Can I eat or take medications before the collection?

A: You can generally eat and take all prescribed medications unless your doctor instructs otherwise. Fasting is not required. For bone marrow aspiration, follow your physician’s specific instructions about blood thinners to minimize bleeding risk.

3. How quickly will I get results and who explains them?

A: Results are available within 3 to 4 days from sample receipt, delivered securely to your physician. Our DHA-licensed clinical team provides complimentary telephonic guidance to help you understand your numeric transcript ratio, but final interpretation and treatment decisions rest with your treating oncologist.

4. What does a low positive result mean after treatment?

A: A low positive result indicates measurable residual disease – a few leukemia cells carrying the fusion gene remain. Stable low levels often suggest a good response to therapy, but a rising trend warrants closer monitoring and possible treatment adjustment. Always discuss with your oncologist.

UAE Regulatory & Data Privacy Adherence

DNA Labs UAE operates under DHA Facility License Number 1143, strictly adhering to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data is encrypted, access-controlled, and processed within secure UAE-based servers. Your protected health information (PHI) is used exclusively for diagnostic purposes and shared only with your consent or as required by law. The laboratory maintains ISO 15189 and ISO 9001:2015 accreditation, ensuring highest standards of quality and confidentiality.

Clinical & Logistical Metadata

Test Name	RUNX1-RUNX1T1 (AML1-ETO) t(8;21) Quantitative
Price (AED)	800
Turnaround Time	3–4 business days
Sample Type / Matrix	Peripheral blood or bone marrow aspirate; bone marrow collection requires hospital visit
Methodology Used	Real-Time Quantitative PCR (qPCR) calibrated to international standards
ICD-10-CM Code	C92.00
LOINC Code	36575-9
DHA Facility License & Laboratory Address	DHA License: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

💬 التحقق عبر الواتساب Verify via WhatsApp 📞 Call Team

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians